Cortical cholinergic transmission and cortical information processing in schizophrenia

Schizophrenia Bulletin

Volumn 31, Issue 1, 2005, Pages 117-138

  Sarter, Martin ^a   Nelson, Christopher L ^b   Bruno, John P ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Acetylcholine; Attention; Cortex; Dopamine; Nucleus accumbens; Schizophrenia

Indexed keywords

ACETYLCHOLINE; DOPAMINE;

BRAIN CORTEX; CHOLINERGIC TRANSMISSION; COGNITION; CORPUS STRIATUM; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROANATOMY; NEUROCHEMISTRY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ATTENTION; CHOLINERGIC NERVE; COGNITIVE DEFECT; MENTAL DISEASE; METABOLISM; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY;

ACETYLCHOLINE; ATTENTION; CEREBRAL CORTEX; CHOLINERGIC FIBERS; COGNITION DISORDERS; DOPAMINE; HUMANS; MENTAL DISORDERS; NUCLEUS ACCUMBENS; SCHIZOPHRENIA;

EID: 20844438007     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/sbi006     Document Type: Review

References (312)

1. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., van Dyck, C.H., Charney, D.S., Innis, R.B., and Laruelle, M. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. American Journal of Psychiatry, 155(6):761-767, 1998.
2. Addington, J., Addington, D., and Maticka-Tyndale, E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia Research, 5(2):123-134, 1991.
3. Adler, L.E., Olincy, A., Waldo, M., Harris, J.G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., and Freedman, R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin, 24(2):189-202, 1998.
4. Alain, C., McNeely, H.E., He, Y., Christensen, B.K., and West, R. Neurophysiological evidence of error-monitoring deficits in patients with schizophrenia. Cerebral Cortex, 12(8):840-846, 2002.
5. Andreasen, N.C. Schizophrenia: The fundamental questions. Brain Research. Brain Research Reviews, 31(2-3):106-112, 2000.
6. Andreasen, N.C., O'Leary, D.S., Cizadlo, T., Arndt, S., Rezai, K., Ponto, L.L., Watkins, G.L., and Hichwa, R.D. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic- cerebellar circuitry. Proceedings of the National Academy of Sciences of the United States of America, 93(18):9985-9990, 1996.
7. Andreasen, N.C., Paradiso, S., and O'Leary, D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry?. Schizophrenia Bulletin, 24(2):203-218, 1998.
8. Anonymous First person account: Portrait of a schizophrenic. Schizophrenia Bulletin, 18(2):333-335, 1992.
9. Aramakis, V.B., Bandrowski, A.E., and Ashe, J.H. Activation of muscarinic receptors modulates NMDA receptor-mediated responses in auditory cortex. Experimental Brain Research, 113(3):484-496, 1997.
10. Arnold, H.M., Burk, J.A., Hodgson, E.M., Sarter, M., and Bruno, J.P. Differential cortical acetylcholine release in rats performing a sustained attention task versus behavioral control tasks that do not explicitly tax attention. Neuroscience, 114(2):451-460, 2002.
11. Bakin, J.S., and Weinberger, N.M. Induction of a physiological memory in the cerebral cortex by stimulation of the nucleus basalis. Proceedings of the National Academy of Sciences of the United States of America, 93(20):11219-11224, 1996.
12. Ball, S., Busatto, G.F., David, A.S., Jones, S.H., Hemsley, D.R., Pilowsky, L.S., Costa, D.C., Ell, P.J., and Kerwin, R.W. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 123I-iomazenil SPET study. Biological Psychiatry, 43(2):107-117, 1998.
13. Bassareo, V., Tanda, G., Petromilli, P., Giua, C., and Di Chiara, G. Non-psychostimulant drugs of abuse and anxiogenic drugs activate with differential selectivity dopamine transmission in the nucleus accumbens and in the medial prefrontal cortex of the rat. Psychopharmacology, 124(4):293-299, 1996.
14. Beckstead, R.M., Domesick, V.B., and Nauta, W.J. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Research, 175(2):191-217, 1979.
15. Bell, D.S. Comparison of amphetamine psychosis and schizophrenia. British Journal of Psychiatry, 111:701-707, 1965.
16. Berman, I., Viegner, B., Merson, A., Allan, E., Pappas, D., and Green, A.I. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia Research, 25(1):1-10, 1997.
17. Berridge, K.C., and Robinson, T.E. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?. Brain Research. Brain Research Reviews, 28(3):309-369, 1998.
18. Bertolino, A., Knable, M.B., Saunders, R.C., Callicott, J.H., Kolachana, B., Mattay, V.S., Bachevalier, J., Frank, J.A., Egan, M., and Weinberger, D.R. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biological Psychiatry, 45(6):660-667, 1999.
19. Bianchi, C., Tanganelli, S., and Beani, L. Dopamine modulation of acetylcholine release from the guinea-pig brain. European Journal of Pharmacology, 58(3):235-246, 1979.
20. Blaha, C.D., Yang, C.R., Floresco, S.B., Barr, A.M., and Phillips, A.G. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. European Journal of Neuroscience, 9(5):902-911, 1997.
21. Bleuler, E. Dementia Praecox or the Group of Schizophrenias. (1911) Translated by J. Zinkin. New York, NY: International Universities Press, 1950.
22. Bodkin, J.A. Emerging uses for high-potency benzodiazepines in psychotic disorders. Journal of Clinical Psychiatry, 51(Suppl):41-46; discussion 50-53, 1990.
23. Bourdelais, A., and Kalivas, P.W. Amphetamine lowers extracellular GABA concentration in the ventral pallidum. Brain Research, 516(1):132-136, 1990.
24. Bourdelais, A., and Kalivas, P.W. Apomorphine decreases extracellular GABA in the ventral pallidum of rats with 6-OHDA lesions in the nucleus accumbens. Brain Research, 577(2):306-311, 1992.
25. Bowers, M.B., Goodman, E., and Sim, V.M. Some behavioral changes in man following anticholinesterase administration. Journal of Nervous and Mental Disease, 138:383-389, 1964.
26. Bradberry, C.W., Lory, J.D., and Roth, R.H. The anxiogenic beta-carboline FG 7142 selectively increases dopamine release in rat prefrontal cortex as measured by microdialysis. Journal of Neurochemistry, 56(3):748-752, 1991.
27. Braff, D.L. Information processing and attention dysfunctions in schizophrenia. Schizophrenia Bulletin, 19(2):233-259, 1993.
28. Brebion, G., Amador, X., Smith, M.J., Malaspina, D., Sharif, Z., and Gorman, J.M. Opposite links of positive and negative symptomatology with memory errors in schizophrenia. Psychiatry Research, 88(1):15-24, 1999.
29. Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K., Eckelman, W.C., and Pickar, D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94(6):2569-2574, 1997.
30. Brockington, I. Schizophrenia: Yesterday's concept. European Psychiatry, 7:203-207, 1992.
31. Brose, N., O'Neill, R.D., Boutelle, M.G., Anderson, S.M., and Fillenz, M. Effects of an anxiogenic benzodiazepine receptor ligand on motor activity and dopamine release in nucleus accumbens and striatum in the rat. Journal of Neuroscience, 7(9):2917-2926, 1987.
32. Brown, V.J., and Bowman, E.M. Discriminative cues indicating reward magnitude continue to determine reaction time of rats following lesions of the nucleus accumbens. European Journal of Neuroscience, 7(12):2479-2485, 1995.
33. Bruno, J.P., and Miller, J. Inhibition of GABAergic transmission: Interactions with other transmitter systems. In: Sarter, M., Nutt, D., and Lister, R., eds. Benzodiazepine Receptor Inverse Agonists. New York, NY: John Wiley and Sons, 1995. pp. 41-82.
34. Bunge, S.A., Ochsner, K.N., Desmond, J.E., Glover, G.H., and Gabrieli, J.D. Prefrontal regions involved in keeping information in and out of mind. Brain, 124(Pt 10):2074-2086, 2001.
35. Burk, J.A., and Sarter, M. Dissociation between the attentional functions mediated via basal forebrain cholinergic and GABAergic neurons. Neuroscience, 105(4):899-909, 2001.
36. Burns, L.H., Everitt, B.J., Kelley, A.E., and Robbins, T.W. Glutamate-dopamine interactions in the ventral striatum: Role in locomotor activity and responding with conditioned reinforcement. Psychopharmacology, 115(4):516-528, 1994.
37. Cadenhead, K.S., and Braff, D.L. Information processing and attention in schizophrenia: Clinical and functional correlates and treatment of cognitive impairment. In: Sharma, T., and Harvey, P., eds. Cognition in Schizophrenia. Oxford, U.K.: Oxford University Press, 2000. pp. 92-106.
38. Cador, M., Bjijou, Y., Cailhol, S., and Stinus, L. D-amphetamine-induced behavioral sensitization: Implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation. Neuroscience, 94(3):705-721, 1999.
39. Cador, M., Robbins, T.W., and Everitt, B.J. Involvement of the amygdala in stimulus-reward associations: Interaction with the ventral striatum. Neuroscience, 30(1):77-86, 1989.
40. Cador, M., Taylor, J.R., and Robbins, T.W. Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology, 104(3):377-385, 1991.
41. Cardinal, R.N., Parkinson, J.A., Hall, J., and Everitt, B.J. Emotion and motivation: The role of the amygdala, ventral striatum, and prefrontal cortex. Neuroscience and Biobehavioral Reviews, 26(3):321-352, 2002.
42. Carpenter, W.T. Jr., Buchanan, R.W., Kirkpatrick, B., and Breier, A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry, 156(2):299-303, 1999.
43. Carr, D.B., O'Donnell, P., Card, J.P., and Sesack, S.R. Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. Journal of Neuroscience, 19(24):11049-11060, 1999.
44. Carr, D.B., and Sesack, S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. Journal of Neuroscience, 20(10):3864-3873, 2000.
45. Castner, S.A., al-Tikriti, M.S., Baldwin, R.M., Seibyl, J.P., Innis, R.B., and Goldman-Rakic, P.S. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology, 22(1):4-13, 2000.
46. Charara, A., and Grace, A.A. Dopamine receptor subtypes selectively modulate excitatory afferents from the hippocampus and amygdala to rat nucleus accumbens neurons. Neuropsychopharmacology, 28(8):1412-1421, 2003.
47. Chiodo, L.A., and Bunney, B.S. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience, 3(8):1607-1619, 1983.
48. Cohen, R.M., Nordahl, T.E., Semple, W.E., Andreason, P., and Pickar, D. Abnormalities in the distributed network of sustained attention predict neuroleptic treatment response in schizophrenia. Neuropsychopharmacology, 19(1):36-47, 1998.
49. Compton, D.R., and Johnson, K.M. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics, 248(2):521-530, 1989.
50. Corbetta, M., and Shulman, G.L. Control of goal-directed and stimulus-driven attention in the brain. Nature Reviews. Neuroscience, 3(3):201-215, 2002.
51. Cornwall, J., and Phillipson, O.T. Afferent projections to the dorsal thalamus of the rat as shown by retrograde lectin transport: II. The midline nuclei. Brain Research Bulletin, 21(2):147-161, 1988.
52. Crider, A., Solomon, P.R., and McMahon, M.A. Disruption of selective attention in the rat following chronic d-amphetamine administration: Relationship to schizophrenic attention disorder. Biological Psychiatry, 17(3):351-361, 1982.
53. Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L., and Dean, B. Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biological Psychiatry, 48(5):381-388, 2000.
54. Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L., and Dean, B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. American Journal of Psychiatry, 158(6):918-925, 2001.
55. Dalack, G.W., Healy, D.J., and Meador-Woodruff, J.H. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. American Journal of Psychiatry, 155(11):1490-1501, 1998.
56. Darracq, L., Drouin, C., Blanc, G., Glowinski, J., and Tassin, J.P. Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. Neuroscience, 103(2):395-403, 2001.
57. Davis, K.L., Berger, P.A., Hollister, L.E., and Barchas, J.D. Cholinergic involvement in mental disorders. Life Sciences, 22(21):1865-1871, 1978.
58. Davis, K.L., Kahn, R.S., Ko, G., and Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. American Journal of Psychiatry, 148(11):1474-1486, 1991.
59. Dawson, M.E., Schell, A.M., Hazlett, E.A., Nuechterlein, K.H., and Filion, D.L. On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Research, 96(3):187-197, 2000.
60. Day, J.C., Tham, C.S., and Fibiger, H.C. Dopamine depletion attenuates amphetamine-induced increases of cortical acetylcholine release. European Journal of Pharmacology, 263(3):285-292, 1994.
61. Delini-Stula, A., and Berdah-Tordjman, D. Benzodiazepines and GABA hypotheses of schizophrenia. Journal of Psychopharmacology, 9:57-63, 1995.
62. Delini-Stula, A., and Berdah-Tordjman, D. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia-a study group report. Journal of Psychiatric Research, 30(4):239-250, 1996.
63. Delini-Stula, A., Berdah-Tordjman, D., and Neumann, N. Partial benzodiazepine agonists in schizophrenia: Expectations and present clinical findings. Clinical Neuropharmacology, 15(Suppl 1, Pt A):405A-406A, 1992.
64. Deller, T., and Sarter, M. Effects of repeated administration of amphetamine on behavioral vigilance: Evidence for "sensitized" attentional impairments. Psychopharmacology, 137(4):410-414, 1998.
65. Desimone, R., and Duncan, J. Neural mechanisms of selective visual attention. Annual Review of Neuroscience, 18:193-222, 1995.
66. Deutch, A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: Implications for schizophrenia and Parkinson's disease. Journal of Neural Transmission. General Section, 91(2-3):197-221, 1993.
67. Dickson, C.T., and Alonso, A. Muscarinic induction of synchronous population activity in the entorhinal cortex. Journal of Neuroscience, 17(17):6729-6744, 1997.
68. Drevets, W.C., Gautier, C., Price, J.C., Kupfer, D.J., Kinahan, P.E., Grace, A.A., Price, J.L., and Mathis, C.A. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry, 49(2):81-96, 2001.
69. Dworkin, R.H., Cornblatt, B.A., Friedmann, R., Kaplansky, L.M., Lewis, J.A., Rinaldi, A., Shilliday, C., and Erlenmeyer-Kimling, L. Childhood precursors of affective vs. social deficits in adolescents at risk for schizophrenia. Schizophrenia Bulletin, 19(3):563-577, 1993.
70. Egan, M.F., Goldberg, T.E., Gscheidle, T., Weirich, M., Bigelow, L.B., and Weinberger, D.R. Relative risk of attention deficits in siblings of patients with schizophrenia. American Journal of Psychiatry, 157(8):1309-1316, 2000.
71. Ellinwood, E.H. Amphetamine psychosis: I. Descriptions of the individuals and process. Journal of Nervous and Mental Disease, 144:273-283, 1967.
72. Ellinwood, E.H., Jr., Sudilovsky, A., and Nelson, L.M. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. American Journal of Psychiatry, 130(10):1088-1093, 1973.
73. Elliott, R., and Sahakian, B.J. The neuropsychology of schizophrenia: Relations with clinical and neurobiological dimensions. Psychological Medicine, 25(3):581-594, 1995.
74. Elvevag, B., Weinberger, D.R., Suter, J.C., and Goldberg, T.E. Continuous performance test and schizophrenia: A test of stimulus-response compatibility, working memory, response readiness, or none of the above?. American Journal of Psychiatry, 157(5):772-780, 2000.
75. Engel, A.K., Fries, P., and Singer, W. Dynamic predictions: Oscillations and synchrony in top-down processing. Nature Reviews. Neuroscience, 2(10):704-716, 2001.
76. Erlenmeyer-Kimling, L., Cornblatt, B.A., Rock, D., Roberts, S., Bell, M., and West, A. The New York High-Risk Project: Anhedonia, attentional deviance, and psychopathology. Schizophrenia Bulletin, 19(1):141-153, 1993.
77. Everitt, B.J., Cador, M., and Robbins, T.W. Interactions between the amygdala and ventral striatum in stimulus-reward associations: Studies using a second-order schedule of sexual reinforcement. Neuroscience, 30(1):63-75, 1989.
78. Everitt, B.J., and Robbins, T.W. Central cholinergic systems and cognition. Annual Review of Psychology, 48:649-684, 1997.
79. Fadel, J., Sarter, M., and Bruno, J.P. Basal forebrain glutamatergic modulation of cortical acetylcholine release. Synapse, 39(3):201-212, 2001.
80. Fallon, J.H., Koziell, D.A., and Moore, R.Y. Catecholamine innervation of the basal forebrain: II. Amygdala, suprarhinal cortex and entorhinal cortex. Journal of Comparative Neurology, 180(3):509-532, 1978.
81. Felder, C.C., Porter, A.C., Skillman, T.L., Zhang, L., Bymaster, F.P., Nathanson, N.M., Hamilton, S.E., Gomeza, J., Wess, J., and McKinzie, D.L. Elucidating the role of muscarinic receptors in psychosis. Life Sciences, 68(22-23):2605-2613, 2001.
82. Ferre, S., O'Connor, W.T., Snaprud, P., Ungerstedt, U., and Fuxe, K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience, 63(3):765-773, 1994.
83. Finch, D.M. Neurophysiology of converging synaptic inputs from the rat prefrontal cortex, amygdala, midline thalamus, and hippocampal formation onto single neurons of the caudate/putamen and nucleus accumbens. Hippocampus, 6(5):495-512, 1996.
84. Finlay, J.M. Mesoprefrontal dopamine neurons and schizophrenia: Role of developmental abnormalities. Schizophrenia Bulletin, 27(3):431-442, 2001.
85. Fisch, R.Z. Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatrica Scandinavica, 75(1):91-94, 1987.
86. Flaum, M., and Schultz, S.K. When does amphetamine-induced psychosis become schizophrenia?. American Journal of Psychiatry, 153(6):812-815, 1996.
87. Floresco, S.B., Blaha, C.D., Yang, C.R., and Phillips, A.G. Dopamine D1 and NMDA receptors mediate potentiation of basolateral amygdala-evoked firing of nucleus accumbens neurons. Journal of Neuroscience, 21(16):6370-6376, 2001a.
88. Floresco, S.B., Blaha, C.D., Yang, C.R., and Phillips, A.G. Modulation of hippocampal and amygdalar-evoked activity of nucleus accumbens neurons by dopamine: Cellular mechanisms of input selection. Journal of Neuroscience, 21(8):2851-2860, 2001b.
89. Floresco, S.B., Todd, C.L., and Grace, A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. Journal of Neuroscience, 21(13):4915-4922, 2001c.
90. Floresco, S.B., Yang, C.R., Phillips, A.G., and Blaha, C.D. Basolateral amygdala stimulation evokes glutamate receptor-dependent dopamine efflux in the nucleus accumbens of the anaesthetized rat. European Journal of Neuroscience, 10(4):1241-1251, 1998.
91. Freedman, R., Waldo, M., Bickford-Wimer, P., and Nagamoto, H. Elementary neuronal dysfunctions in schizophrenia. Schizophrenia Research, 4(2):233-243, 1991.
92. Frith, C., and Dolan, R. The role of the prefrontal cortex in higher cognitive functions. Brain Research. Cognitive Brain Research, 5(1-2):175-181, 1996.
93. Garavan, H., Ross, T.J., Li, S.J., and Stein, E.A. A parametric manipulation of central executive functioning. Cerebral Cortex, 10(6):585-592, 2000.
94. Gaykema, R.P., and Zaborszky, L. Direct catecholaminergic-cholinergic interactions in the basal forebrain: II. Substantia nigra-ventral tegmental area projections to cholinergic neurons. Journal of Comparative Neurology, 374(4):555-577, 1996.
95. Gerber, D.J., Sotnikova, T.D., Gainetdinov, R.R., Huang, S.Y., Caron, M.G., and Tonegawa, S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 98(26):15312-15317, 2001.
96. Gershon, S., and Shaw, F.H. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet, 1:1371-1374, 1961.
97. Gill, T.M., Masters, J., Sarter, M., and Givens, B. The role of acetylcholine within the medial prefrontal and posterior parietal cortices during sustained visual attention in the rat. [Abstract]. Abstracts-Society for Neuroscience, 25:1895, 1999.
98. Gill, T.M., Sarter, M., and Givens, B. Sustained visual attention performance-associated prefrontal neuronal activity: Evidence for cholinergic modulation. Journal of Neuroscience, 20(12):4745-4757, 2000.
99. Givens, B.; Gill, T.M.; and Spare, S. Correlated firing in the medial prefrontal cortex: Relationship to sustained visual attention. Experimental Brain Research, submitted for publication.
100. Givens, B., and Sarter, M. Modulation of cognitive processes by transsynaptic activation of the basal forebrain. Behavioural Brain Research, 84(1-2):1-22, 1997.
101. Gluck, M.R., Thomas, R.G., Davis, K.L., and Haroutunian, V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. American Journal of Psychiatry, 159(7):1165-1173, 2002.
102. Goldberg, T.E., Patterson, K.J., Taqqu, Y., and Wilder, K. Capacity limitations in short-term memory in schizophrenia: Tests of competing hypotheses. Psychological Medicine, 28(3):665-673, 1998.
103. Goldman-Rakic, P.S., and Selemon, L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bulletin, 23(3):437-458, 1997.
104. Grace, A.A. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. Journal of Neural Transmission. General Section, 91(2-3):111-134, 1993.
105. Grace, A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research. Brain Research Reviews, 31(2-3):330-341, 2000.
106. Grace, A.A., Bunney, B.S., Moore, H., and Todd, C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends in Neurosciences, 20(1):31-37, 1997.
107. Granholm, E., Asarnow, R.F., and Marder, S.R. Controlled information processing resources and the development of automatic detection responses in schizophrenia. Journal of Abnormal Psychology, 100(1):22-30, 1991.
108. Gray, J.A. Dopamine release in the nucleus accumbens: The perspective from aberrations of consciousness in schizophrenia. Neuropsychologia, 33(9):1143-1153, 1995.
109. Gray, J.A. Integrating schizophrenia. Schizophrenia Bulletin, 24(2):249-266, 1998.
110. Gray, J.A., Feldon, J., Rawlins, J.N.P., Hemsley, D.R., and Smith, A.D. The neuropsychology of schizophrenia. Behavioral and Brain Science, 14:1-84, 1991.
111. Green, M.F., Kern, R.S., Braff, D.L., and Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophrenia Bulletin, 26(1):119-136, 2000.
112. Green, M.F., and Nuechterlein, K.H. Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin, 25(2):309-319, 1999.
113. Grillon, C., Courchesne, E., Ameli, R., Geyer, M.A., and Braff, D.L. Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence. Archives of General Psychiatry, 47(2):171-179, 1990.
114. Hamamura, T., and Fibiger, H.C. Enhanced stress-induced dopamine release in the prefrontal cortex of amphetamine-sensitized rats. European Journal of Pharmacology, 237(1):65-71, 1993.
115. Haroutunian, V., Davidson, M., Kanof, P.D., Perl, D.P., Powchik, P., Losonczy, M., McCrystal, J., Purohit, D.P., Bierer, L.M., and Davis, K.L. Cortical cholinergic markers in schizophrenia. Schizophrenia Research, 12(2):137-144, 1994.
116. Hasselmo, M.E., and Bower, J.M. Cholinergic suppression specific to intrinsic not afferent fiber synapses in rat piriform (olfactory) cortex. Journal of Neurophysiology, 67(5):1222-1229, 1992.
117. Heimer, L. Basal forebrain in the context of schizophrenia. Brain Research. Brain Research Reviews, 31(2-3):205-235, 2000.
118. Holley, L.A., Turchi, J., Apple, C., and Sarter, M. Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain. Psychopharmacology, 120(1):99-108, 1995.
119. Hopfinger, J.B., Buonocore, M.H., and Mangun, G.R. The neural mechanisms of top-down attentional control. Nature Neuroscience, 3(3):284-291, 2000.
120. Howland, J.G., Taepavarapruk, P., and Phillips, A.G. Glutamate receptor-dependent modulation of dopamine efflux in the nucleus accumbens by basolateral, but not central, nucleus of the amygdala in rats. Journal of Neuroscience, 22(3):1137-1145, 2002.
121. Hreib, K.K., Rosene, D.L., and Moss, M.B. Basal forebrain efferents to the medial dorsal thalamic nucleus in the rhesus monkey. Journal of Comparative Neurology, 277(3):365-390, 1988.
122. Hyde, T.M., and Crook, J.M. Cholinergic systems and schizophrenia: Primary pathology or epiphenomena?. Journal of Chemical Neuroanatomy, 22(1-2):53-63, 2001.
123. Ichikawa, J., Dai, J., O'Laughlin, I.A., Fowler, W.L., and Meltzer, H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26(3):325-339, 2002.
124. Imperato, A., Puglisi-Allegra, S., Grazia Scrocco, M., Casolini, P., Bacchi, S., and Angelucci, L. Cortical and limbic dopamine and acetylcholine release as neurochemical correlates of emotional arousal in both aversive and non-aversive environmental changes. Neurochemistry International, 20(Suppl):265S-270S, 1992.
125. Ingham, C.A., Bolam, J.P., and Smith, A.D. GABA-immunoreactive synaptic boutons in the rat basal forebrain: Comparison of neurons that project to the neocortex with pallidosubthalamic neurons. Journal of Comparative Neurology, 273(2):263-282, 1988.
126. Jaspert, A., and Ebert, D. Benzodiazepine monotherapy in acute schizophrenia. Der Nervenarzt, 65(1):62-65, 1994.
127. Javitt, D.C., Shelley, A.M., Silipo, G., and Lieberman, J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: Defining the pattern. Archives of General Psychiatry, 57(12):1131-1137, 2000.
128. Jentsch, J.D., Dazzi, L., Chhatwal, J.P., Verrico, C.D., and Roth, R.H. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neuroscience Letters, 258(3):175-178, 1998a.
129. Jentsch, J.D., Taylor, J.R., Elsworth, J.D., Redmond, D.E. Jr., and Roth, R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: Involvement in frontostriatal cognitive deficits. Neuroscience, 90(3):823-832, 1999.
130. Jentsch, J.D., Taylor, J.R., and Roth, R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology, 19(2):105-113, 1998b.
131. Johnstone, E.G., Crow, T.J., Ferrier, I.N., Frith, C.D., Owens, D.G., Bourne, R.C., and Gamble, S.J. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine, 13(3):513-527, 1983.
132. Jolkkonen, E., Miettinen, R., Pikkarainen, M., and Pitkanen, A. Projections from the amygdaloid complex to the magnocellular cholinergic basal forebrain in rat. Neuroscience, 111(1):133-149, 2002.
133. Jones, S.H., Hemsley, D., Ball, S., and Serra, A. Disruption of the Kamin blocking effect in schizophrenia and in normal subjects following amphetamine. Behavioural Brain Research, 88(1):103-114, 1997.
134. Kapur, S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry, 160(1):13-23, 2003.
135. Karczmar, A.G. Basic phenomena underlying novel use of cholinergic agents, anticholinesterases and precursors in neurological including peripheral and psychiatric disease. In: Pepeu, G., and Ladisnky, H., eds. Cholinergic Mechanisms. New York, NY: Plenum Press, 1981. pp. 853-869.
136. Kastner, S., De Weerd, P., Desimone, R., and Ungerleider, L.G. Mechanisms of directed attention in the human extrastriate cortex as revealed by functional MRI. Science, 282(5386):108-111, 1998.
137. Kegeles, L.S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J.J., Van Heertum, R.L., Cooper, T.B., Carlsson, A., and Laruelle, M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biological Psychiatry, 48(7):627-640, 2000.
138. Kelley, A.E., Domesick, V.B., and Nauta, W.J. The amygdalostriatal projection in the rat-an anatomical study by anterograde and retrograde tracing methods. Neuroscience, 7(3):615-630, 1982.
139. Kim, J.J., Kwon, J.S., Park, H.J., Youn, T., Kang do, H., Kim, M.S., Lee, D.S., and Lee, M.C. Functional disconnection between the prefrontal and parietal cortices during working memory processing in schizophrenia: A [15(O)]H2O PET study. American Journal of Psychiatry, 160(5):919-923, 2003.
140. Kimura, F., and Baughman, R.W. Distinct muscarinic receptor subtypes suppress excitatory and inhibitory synaptic responses in cortical neurons. Journal of Neurophysiology, 77(2):709-716, 1997.
141. Kirkpatrick, B., Buchanan, R.W., Waltrip, R.W., 2nd, Jauch, D., and Carpenter, W.T., Jr. Diazepam treatment of early symptoms of schizophrenic relapse. Journal of Nervous and Mental Disease, 177(1):52-53, 1989.
142. Kitamura, M., Ikeda, H., Koshikawa, N., and Cools, A.R. GABA(A) agents injected into the ventral pallidum differentially affect dopaminergic pivoting and cholinergic circling elicited from the shell of the nucleus accumbens. Neuroscience, 104(1):117-127, 2001.
143. Kolb, B., Gorny, G., Li, Y., Samaha, A.N., and Robinson, T.E. Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America, 100(18):10523-10528, 2003.
144. Kraepelin, E. Lectures on Clinical Psychiatry [1904]. Third English Edition. Johnston, T. ed. New York, NY: William Wood and Company, 1912.
145. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., and Charney, D.S. Jr. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3):199-214, 1994.
146. Lahti, A.C., Holcomb, H.H., Gao, X.M., and Tamminga, C.A. NMDA-sensitive glutamate antagonism: A human model for psychosis. Neuropsychopharmacology, 21:8158-8169, 1999.
147. Laruelle, M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Research. Brain Research Reviews, 31(2-3):371-384, 2000.
148. Laruelle, M., and Abi-Dargham, A. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. Journal of Psychopharmacology, 13(4):358-371, 1999.
149. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., and Innis, R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biological Psychiatry, 46(1):56-72, 1999.
150. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., Baldwin, R.M., Seibyl, J.P., Krystal, J.H., Charney, D.S., and Innis, R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93(17):9235-9240, 1996.
151. Lavin, A., and Grace, A.A. Dopamine modulates the responsivity of mediodorsal thalamic cells recorded in vitro. Journal of Neuroscience, 18(24):10566-10578, 1998.
152. Lawrie, S.M., Buechel, C., Whalley, H.C., Frith, C.D., Friston, K.J., and Johnstone, B.C. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biological Psychiatry, 51(12):1008-1011, 2002.
153. LeDuc, P.A., and Mittleman, G. Schizophrenia and psychostimulant abuse: A review and re-analysis of clinical evidence. Psychopharmacology,
154. Lewis, D.A., and Levitt, P. Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience, 25:409-432, 2002.
155. Lewis, D.A., Pierri, J.N., Volk, D.W., Melchitzky, D.S., and Woo, T.U. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biological Psychiatry, 46(5):616-626, 1999.
156. Lieberman, J.A., Kinon, B.J., and Loebel, A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin, 16(1):97-110, 1990.
157. Lieberman, J.A., Sheitman, B.B., and Kinon, B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology, 17(4):205-229, 1997.
158. Light, G. A., and Braff, D.L. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients?. Biological Psychiatry, 47(5):463-467, 2000.
159. Liljenstrom, H., and Hasselmo, M.E. Cholinergic modulation of cortical oscillatory dynamics. Journal of Neurophysiology, 74(1):288-297, 1995.
160. Lindstrom, L.H., Gefvert, O., Hagberg, G., Lundberg, T., Bergstrom, M., Hartvig, P., and Langstrom, B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biological Psychiatry, 46(5):681-688, 1999.
161. Llorca, P.M., Wolf, M.A., and Estorges, J.P. The use of benzodiazepines in schizophrenia: A review. European Journal of Psychiatry, 6:217-222, 1991.
162. Macaluso, E., Frith, C.D., and Driver, J. Directing attention to locations and to sensory modalities: Multiple levels of selective processing revealed with PET. Cerebral Cortex, 12(4):357-368, 2002.
163. Mach, R.H., Voytko, M.L., Ehrenkaufer, R.L., Nader, M.A., Tobin, J.R., Efange, S.M., Parsons, S.M., Gage, H.D., Smith, C.R., and Morton, T.E. Imaging of cholinergic terminals using the radiotracer [18F](+)-4- fluorobenzyltrozamicol: In vitro binding studies and positron emission tomography studies in nonhuman primates. Synapse, 25(4):368-380, 1997.
164. Mancama, D., Arranz, M.J., Landau, S., and Kerwin, R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. American Journal of Medical Genetics, 119B(1):2-6, 2003.
165. Mar, C.M., Smith, D.A., and Sarter, M. Behavioural vigilance in schizophrenia. Evidence for hyperattentional processing. British Journal of Psychiatry, 169(6):781-789, 1996.
166. Marcus, J., Hans, S.L., Auerbach, J.G., and Auerbach, A.G. Children at risk for schizophrenia: The Jerusalem Infant Development Study: II. Neurobehavioral deficits at school age. Archives of General Psychiatry, 50(10):797-809, 1993.
167. Marks, M.J., O'Connor, M.F., Artman, L.D., Burch, J.B., and Collins, A.C. Chronic scopolamine treatment and brain cholinergic function. Pharmacology, Biochemistry, and Behavior, 20(5):771-777, 1984.
168. Martinez, V., Burk, J.A., Sarter, M., and Bruno, J.P. Effects of repeated amphetamine administration on attentional performance in rats. [Abstract]. Abstracts-Society for Neuroscience, 29:516.6, 2003.
169. McCormick, D.A., Wang, Z., and Huguenard, J. Neurotransmitter control of neocortical neuronal activity and excitability. Cerebral Cortex, 3(5):387-398, 1993.
170. McCullough, L.D., and Salamone, J.D. Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens. Psychopharmacology, 109(3):379-382, 1992.
171. McGaughy, J., Kaiser, T., and Sarter, M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: Selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behavioral Neuroscience, 110(2):247-265, 1996.
172. McGaughy, J., and Sarter, M. Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: Effects of physostigmine and FG 7142. Behavioral Neuroscience, 112(6):1519-1525, 1998.
173. McGhie, A., and Chapman, J. Disorders of attention and perception in early schizophrenia. British Journal of Medical Psychology, 34:103-117, 1961.
174. McKenna, T.M., Ashe, J.H., and Weinberger, N.M. Cholinergic modulation of frequency receptive fields in auditory cortex: I. Frequency-specific effects of muscarinic agonists. Synapse, 4(1):30-43, 1989.
175. McLin, D.E., 3rd, Miasnikov, A.A., and Weinberger, N.M. Induction of behavioral associative memory by stimulation of the nucleus basalis. Proceedings of the National Academy of Sciences of the United States of America, 99(6):4002-4007, 2002.
176. Mele, A., Thomas, D.N., and Pert, A. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity. Neuroscience, 82(1):43-58, 1998.
177. Meredith, G.E. The synaptic framework for chemical signaling in nucleus accumbens. Annals of the New York Academy of Sciences, 877:140-156, 1999.
178. Mesulam, M.M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Annals of Neurology, 28(5):597-613, 1990.
179. Miller, E.K., and Cohen, J.D. An integrative theory of prefrontal cortex function. Annual Review of Neuroscience, 24:167-202, 2001.
180. Mirsky, A.F., Yardley, S.L., Jones, B.P., Walsh, D., and Kendler, K.S. Analysis of the attention deficit in schizophrenia: A study of patients and their relatives in Ireland. Journal of Psychiatric Research, 29(1):23-42, 1995.
181. Mogenson, G.J., Ciriello, J., Garland, J., and Wu, M. Ventral pallidum projections to mediodorsal nucleus of the thalamus: An anatomical and electrophysiological investigation in the rat. Brain Research, 404(1-2):221-230, 1987.
182. Mogenson, G.J., Swanson, L.W., and Wu, M. Neural projections from nucleus accumbens to globus pallidus, substantia innominata, and lateral preoptic-lateral hypothalamic area: An anatomical and electrophysiological investigation in the rat. Journal of Neuroscience, 3(1):189-202, 1983.
183. Moghaddam, B. Stress activation of glutamate neurotransmission in the prefrontal cortex: Implications for dopamine-associated psychiatric disorders. Biological Psychiatry, 51(10):775-787, 2002.
184. Momiyama, T., and Sim, J. A. Modulation of inhibitory transmission by dopamine in rat basal forebrain nuclei: Activation of presynaptic D1-like dopaminergic receptors. Journal of Neuroscience, 16(23):7505-7512, 1996.
185. Moore, H., Fadel, J., Sarter, M., and Bruno, J.P. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience, 88(3):811-822, 1999a.
186. Moore, H., Sarter, M., and Bruno, J.P. Bidirectional modulation of cortical acetylcholine efflux by infusion of benzodiazepine receptor ligands into the basal forebrain. Neuroscience Letters, 189(1):31-34, 1995a.
187. Moore, H., Stuckman, S., Sarter, M., and Bruno, J.P. Stimulation of cortical acetylcholine efflux by FG 7142 measured with repeated microdialysis sampling. Synapse, 21(4):324-331, 1995b.
188. Moore, H., West, A.R., and Grace, A.A. The regulation of forebrain dopamine transmission: Relevance to the pathophysiology and psychopathology of schizophrenia. Biological Psychiatry, 46(1):40-55, 1999b.
189. Mulder, A.B., Hodenpijl, M.G., and Lopes da Silva, F.H. Electrophysiology of the hippocampal and amygdaloid projections to the nucleus accumbens of the rat: Convergence, segregation, and interaction of inputs. Journal of Neuroscience, 18(13):5095-5102, 1998.
190. Mulholland, G.K., Wieland, D.M., Kilbourn, M.R., Frey, K.A., Sherman, P.S., Carey, J.E., and Kuhl, D.E. [18F]fluoroethoxybenzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse, 30(3):263-274, 1998.
191. Muller, C.M., and Singer, W. Acetylcholine-induced inhibition in the cat visual cortex is mediated by a GABAergic mechanism. Brain Research, 487(2):335-342, 1989.
192. Murphy, B.L., Arnsten, A.F., Goldman-Rakic, P.S., and Roth, R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proceedings of the National Academy of Sciences of the United States of America, 93(3):1325-1329, 1996a.
193. Murphy, B.L., Arnsten, A.F., Jentsch, J.D., and Roth, R.H. Dopamine and spatial working memory in rats and monkeys: Pharmacological reversal of stress-induced impairment. Journal of Neuroscience, 16(23):7768-7775, 1996e.
194. Murphy, C.A., Di Iorio, L., and Feldon, J. Effects of psychostimulant withdrawal on latent inhibition of conditioned active avoidance and prepulse inhibition of the acoustic startle response. Psychopharmacology, 156(2-3):155-164, 2001.
195. Mussgay, L., and Hertwig, R. Signal detection indexes in schizophrenics on a visual, auditory, and bimodal Continuous Performance Test. Schizophrenia Research, 3(5-6):303-310, 1990.
196. Napier, T.C., Mitrovic, I., Churchill, L., Klitenick, M.A., Lu, X.Y., and Kalivas, P.W. Substance p in the ventral pallidum: Projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P. Neuroscience, 69(1):59-70, 1995.
197. Neigh-McCandless, G., Kravitz, B.A., Sarter, M., and Bruno, J.P. Stimulation of cortical acetylcholine release following blockade of ionotropic glutamate receptors in nucleus accumbens. European Journal of Neuroscience, 16(7):1259-1266, 2002.
198. Nelson, C.L., Burk, J.A., Bruno, J.P., and Sarter, M. Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacology, 161(2):168-179, 2002a.
199. Nelson, C.L., Sarter, M., and Bruno, J.P. Repeated pretreatment with amphetamine sensitizes increases in cortical acetylcholine release. Psychopharmacology, 151(4):406-415, 2000.
200. Nelson, C.L., Sarter, M., and Bruno, J.P. Glutamatergic or cholinergic stimulation of the medial prefrontal cortex increases acetylcholine release in the posterior parietal cortex. [Abstract]. Abstracts: Society for Neuroscience, 28:674.7, 2002b.
201. Nelson, E.B., Sax, K.W., and Strakowski, S.M. Attentional performance in patients with psychotic and nonpsychotic major depression and schizophrenia. American Journal of Psychiatry, 155(1):137-139, 1998.
202. Newcomer, J.W., Farber, N.B., Jevtovic-Todorovic, V., Selke, G., Melson, A.K., Hershey, T., Craft, S., and Olney, J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, 20(2):106-118, 1999.
203. Nicola, S.M., Surmeier, J., and Malenka, R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annual Review of Neuroscience, 23:185-215, 2000.
204. Nielsen, E.B. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology, 94(1):115-118, 1988.
205. Ninan, I., and Kulkarni, S.K. Effect of olanzapine on behavioural changes induced by FG 7142 and dizocilpine on active avoidance and plus maze tasks. Brain Research, 830(2):337-344, 1999.
206. Nishiyama, S., Sato, K., Harada, N., Kakiuchi, T., and Tsukada, H. Development and evaluation of muscarinic cholinergic receptor ligands N-[11C]ethyl-4-piperidyl benzilate and N-[11C]propyl-4-piperidyl benzilate: A PET study in comparison with N-[11C]methyl-4-piperidyl benzilate in the conscious monkey brain. Nuclear Medicine and Biology, 27(8):733-740, 2000.
207. Nuechterlein, K.H., and Dawson, M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin, 10(2):160-203, 1984.
208. O'Donnell, P. Ensemble encoding in the nucleus accumbens. Psychobiology, 27:187-197, 1999.
209. O'Donnell, P., and Grace, A.A. Dopaminergic modulation of dye coupling between neurons in the core and shell regions of the nucleus accumbens. Journal of Neuroscience, 13(8):3456-3471, 1993.
210. O'Donnell, P., and Grace, A.A. Dopaminergic reduction of excitability in nucleus accumbens neurons recorded in vitro. Neuropsychopharmacology, 15(1):87-97, 1996.
211. O'Donnell, P., and Grace, A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophrenia Bulletin, 24(2):267-283, 1998.
212. O'Donnell, P., Lavin, A., Enquist, L.W., Grace, A.A., and Card, J.P. Interconnected parallel circuits between rat nucleus accumbens and thalamus revealed by retrograde transynaptic transport of pseudorabies virus. Journal of Neuroscience, 17(6):2143-2167, 1997.
213. Ojeda, N., Ortuno, F., Arbizu, J., Lopez, P., Marti-Climent, J.M., Penuelas, I., and Cervera-Enguix, S. Functional neuroanatomy of sustained attention in schizophrenia: Contribution of parietal cortices. Human Brain Mapping, 17(2):116-130, 2002.
214. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., Iyo, M., Tateno, Y., and Toru, M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385(6617):634-636, 1997.
215. Parada, M.A., Hernandez, L., Puig de Parada, M., Rada, P., and Murzi, E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. Journal of Pharmacology and Experimental Therapeutics, 281(1):582-588, 1997.
216. Patel, S., and Slater, P. Effects of GABA compounds injected into the subpallidal regions of rat brain on nucleus accumbens evoked hyperactivity. Behavioral Neuroscience, 102(4):596-600, 1988.
217. Paulson, P.E., Camp, D.M., and Robinson, T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology, 103(4):480-492, 1991.
218. Perry, E.K., and Perry, R.H. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain and Cognition, 28(3):240-258, 1995.
219. Perry, W., Geyer, M.A., and Braff, D.L. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Archives of General Psychiatry, 56(3):277-281, 1999.
220. Phillips, M.L., and David, A.S. Cognitive impairments as causes of positive symptoms in schizophrenia. In: Sharma, T., and Harvey, P., eds. Cognition in Schizophrenia. Oxford, U.K.: Oxford University Press, 2000. pp. 210-228.
221. Pierce, R.C., and Kalivas, P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Research. Brain Research Reviews, 25(2):192-216, 1997.
222. Posner, M.I., and Dehaene, S. Attentional networks. Trends in Neurosciences, 17(2):75-79, 1994.
223. Potts, G.F., O'Donnell, B.F., Hirayasu, Y., and McCarley, R.W. Disruption of neural systems of visual attention in schizophrenia. Archives of General Psychiatry, 59(5):418-424, 2002.
224. Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S.M., Purohit, D.P., Perl, D.P., Harvey, P.D., and Davis, K.L. Post-mortem studies in schizophrenia. Schizophrenia Bulletin, 24(3):325-341, 1998.
225. Raedler, T.J., Knable, M.B., Jones, D.W., Lafargue, T., Urbina, R.A., Egan, M.F., Pickar, D., and Weinberger, D.R. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology, 23(1):56-68, 2000.
226. Raedler, T.J., Knable, M.B., Jones, D.W., Urbina, R.A., Gorey, J.G., Lee, K.S., Egan, M.F., Coppola, R., and Weinberger, D.R. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. American Journal of Psychiatry, 160(1):118-127, 2003.
227. Rasmusson, D.D., and Dykes, R.W. Long-term enhancement of evoked potentials in cat somatosensory cortex produced by co-activation of the basal forebrain and cutaneous receptors. Experimental Brain Research, 70(2):276-286, 1988.
228. Robinson, T.E., and Becker, J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Research, 396(2):157-198, 1986.
229. Robinson, T.E., and Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research. Brain Research Reviews, 18(3):247-291, 1993.
230. Rosenkranz, J.A., and Grace, A.A. Cellular mechanisms of infra-limbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. Journal of Neuroscience, 22(1):324-337, 2002.
231. Rylander, G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatrica, Neurologia, Neurochirurgia, 75(3):203-212, 1972.
232. Salamone, J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behavioural Brain Research, 61(2):117-133, 1994.
233. Salo, R., Robertson, L.C., and Nordahl, T.E. Normal sustained effects of selective attention are absent in schizophrenic patients withdrawn from medication. Psychiatry Research, 62(2):121-130, 1996.
234. Salokangas, R.K., Saarijarvi, S., Taiminen, T., Lehto, H., Niemi, H., Ahola, V., and Syvalahti, E. Effect of smoking on neuroleptics in schizophrenia. Schizophrenia Research, 23(1):55-60, 1997.
235. Sarter, M., and Bruno, J.P. Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neurosciences, 22(2):67-74, 1999.
236. Sarter, M., and Bruno, J.P. The neglected constituent of the basal forebrain corticopetal projection system: GABAergic projections. European Journal of Neuroscience, 15(12):1867-1873, 2002.
237. Sarter, M., Bruno, J.P., and Berntson, G.G. Psychotogenic properties of benzodiazepine receptor inverse agonists. Psychopharmacology, 156(1):1-13, 2001a.
238. Sarter, M., Bruno, J.P., and Dudchenko, P. Activating the damaged basal forebrain cholinergic system: Tonic stimulation versus signal amplification. Psychopharmacology, 101(1):1-17, 1990.
239. Sarter, M., Givens, B., and Bruno, J.P. The cognitive neuroscience of sustained attention: Where top-down meets bottom-up. Brain Research. Brain Research Reviews, 35(2):146-160, 2001b.
240. Sarter, M., and Markowitsch, H.J. Collateral innervation of the medial and lateral prefrontal cortex by amygdaloid, thalamic, and brain-stem neurons. Journal of Comparative Neurology, 224(3):445-460, 1984.
241. Sarter, M.F., and Bruno, J.P. Cognitive functions of cortical ACh: Lessons from studies on trans-synaptic modulation of activated efflux. Trends in Neurosciences, 17(6):217-221, 1994.
242. Sato, H., Hata, Y., Masui, H., and Tsumoto, T. A functional role of cholinergic innervation to neurons in the cat visual cortex. Journal of Neurophysiology, 58(4):765-780, 1987.
243. Schultz, W., Dayan, P., and Montague, P.R. A neural substrate of prediction and reward. Science, 275(5306):1593-1599, 1997.
244. Seeman, P., and Kapur, S. Schizophrenia: More dopamine, more D2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 97(14):7673-7675, 2000.
245. Segal, D.S., Geyer, M.A., and Schuckit, M.A. Stimulant-induced psychosis: An evaluation of animal methods. In: Youdim, M.B.H., Lovenberg, W., Sharman, D.F., and Lagnado, J.R., eds. Essays in Neurochemistry and Neuropharmacology. Sussex, U.K.: Wiley, 1981. pp. 95-129.
246. Segal, D.S., and Janowski, D.S. Psychostimulant-induced behavioral effects: Possible models of schizophrenia. In: Lipton, M.A., DiMascio, A., and Killam, K.F., eds. Psychopharmacology: A Generation of Progress. New York, NY: Raven Press, 1978. pp. 1113-1124.
247. Seidman, L.J., Van Manen, K.J., Turner, W.M., Gamser, D.M., Faraone, S.V., Goldstein, J.M., and Tsuang, M.T. The effects of increasing resource demand on vigilance performance in adults with schizophrenia or developmental attentional/learning disorders: A preliminary study. Schizophrenia Research, 34(1-2):101-112, 1998.
248. Serper, M.R., Davidson, M., and Harvey, P.D. Attentional predictors of clinical change during neuroleptic treatment in schizophrenia. Schizophrenia Research, 13(1):65-71, 1994.
249. Servan-Schreiber, D., Cohen, J.D., and Steingard, S. Schizophrenic deficits in the processing of context. A test of a theoretical model. Archives of General Psychiatry, 53(12):1105-1112, 1996.
250. Sesack, S.R., and Pickel, V.M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Research, 527(2):266-279, 1990.
251. Sethy, V.H., Ellerbrock, B.R., and Wu, H. Comparative dopaminergic and muscarinic antagonist activity of clozapine and haloperidol. Life Sciences, 58(7):585-590, 1996.
252. Shakow, D. Segmental set: A theory of the formal psychological deficit in schizophrenia. Biological Psychology, 46:600-615, 1962.
253. Shannon, H.E., Hart, J.C., Bymaster, P.P., Calligaro, D.O., DeLapp, N.W., Mitch, C.H., Ward, J.S., Fink-Jensen, A., Sauerberg, P., Jeppesen, L., Sheardown, M.J., and Swedberg, M.D. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. Journal of Pharmacology and Experimental Therapeutics, 290(2):901-907, 1999.
254. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D., Jeppesen, L., Sheardown, M.J., Sauerberg, P., and Fink-Jensen, A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia Research, 42(3):249-259, 2000.
255. Sharp, F.R., Tomitaka, M., Bernaudin, M., and Tomitaka, S. Psychosis: Pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends in Neurosciences, 24(6):330-334, 2001.
256. Shirazi-Southall, S., Rodriguez, D.E., and Nomikos, G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26(5):583-594, 2002.
257. Shulman, G.L., Corbetta, M., Buckner, R.L., Raichle, M.E., Fiez, J.A., Miezin, F.M., and Petersen, S.E. Top-down modulation of early sensory cortex. Cerebral Cortex, 7(3):193-206, 1997.
258. Smiley, J.F., Subramanian, M., and Mesulam, M.M. Monoaminergic- cholinergic interactions in the primate basal forebrain. Neuroscience, 93(3):817-829, 1999.
259. Smith, G.L., Large, M.M., Kavanagh, D.J., Karayanidis, F., Barrett, N.A., Michie, P.T., and O'Sullivan, B.T. Further evidence for a deficit in switching attention in schizophrenia. Journal of Abnormal Psychology, 107(3):390-398, 1998.
260. Soares, J.C., and Innis, R.B. Neurochemical brain imaging investigations of schizophrenia. Biological Psychiatry, 46(5):600-615, 1999.
261. Spring, B. Cognitive alterations as markers of vulnerability to schizophrenia. In: Friedman, D., and Bruder, G., eds. Psychophysiology and Experimental Psychopathology: A Tribute to Samuel Sutton. New York, NY: New York Academy of Sciences, 1992. pp. 128-145.
262. Stanhope, K.J., Mirza, N.R., Bickerdike, M.J., Bright, J.L., Harrington, N.R., Hesselink, M.B., Kennett, G.A., Lightowler, S., Sheardown, M.J., Syed, R., Upton, R.L., Wadsworth, G., Weiss, S.M., and Wyatt, A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. Journal of Pharmacology and Experimental Therapeutics, 299(2):782-792, 2001.
263. Stephans, S.E., and Yamamoto, B.Y. Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex. Brain Research, 700(1-2):99-106, 1995.
264. Strakowski, S.M., Sax, K.W., Setters, M.J., Stanton, S.P., and Keck, P.E., Jr. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: Implications for a sensitization model of psychosis in humans. Biological Psychiatry, 42(9):749-755, 1997.
265. Strauss, M.E., Reynolds, K.S., Jayaram, G., and Tune, L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research, 3(2):127-129, 1990.
266. Swerdlow, N.R., Braff, D.L., and Geyer, M.A. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Research, 532(1-2):146-150, 1990a.
267. Swerdlow, N.R., Mansbach, R.S., Geyer, M.A., Pulvirenti, L., Koob, G.F., and Braff, D.L. Amphetamine disruption of pre-pulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology, 100(3):413-416, 1990e.
268. Swerdlow, N.R., Swanson, L.W., and Koob, G.F. Substantia innominata: Critical link in the behavioral expression of mesolimbic dopamine stimulation in the rat. Neuroscience Letters, 50(1-3):19-24, 1984.
269. Taber, M.T., and Fibiger, H.C. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: Modulation by metabotropic glutamate receptors. Journal of Neuroscience, 15(5 Pt 2):3896-3904, 1995.
270. Taber, M.T., and Fibiger, H.C. Feeding-evoked dopamine release in the nucleus accumbens: Regulation by glutamatergic mechanisms. Neuroscience, 76(4):1105-1112, 1997.
271. Tam, S.Y., and Roth, R.H. Selective increase in dopamine metabolism in the prefrontal cortex by the anxiogenic beta-carboline FG 7142. Biochemical Pharmacology, 34(9):1595-1598, 1985.
272. Tandon, R., and Greden, J.F. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry, 46(8):745-753, 1989.
273. Tandon, R., Greden, J.F., and Haskett, R.F. Cholinergic hyperactivity and negative symptoms: Behavioral effects of physostigmine in normal controls. Schizophrenia Research, 9(1):19-23, 1993.
274. Tandon, R., Taylor, S.F., DeQuardo, J.R., Eiser, E., Jibson, M.D., and Goldman, M. The cholinergic system in schizophrenia reconsidered. Neuropsychopharmacology, 22:8189-8202, 1999.
275. Tang, A.C., Bartels, A.M., and Sejnowski, T.J. Effects of cholinergic modulation on responses of neocortical neurons to fluctuating input. Cerebral Cortex, 7(6):502-509, 1997.
276. Thiel, C.M., Bentley, P., and Dolan, R.J. Effects of cholinergic enhancement on conditioning-related responses in human auditory cortex. European Journal of Neuroscience, 16(11):2199-2206, 2002.
277. Treue, S. Neural correlates of attention in primate visual cortex. Trends in Neurosciences, 24(5):295-300, 2001.
278. Tsukada, H., Kakiuchi, T., Nishiyama, S., Ohba, H., Sato, K., Harada, N., and Takahashi, K. Age differences in muscarinic cholinergic receptors assayed with (+)N-[(11)C]methyl-3-piperidyl benzilate in the brains of conscious monkeys. Synapse, 41(3):248-257, 2001.
279. Tsukada, H., Nishiyama, S., Kakiuchi, T., Ohba, H., Sato, K., and Harada, N. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Research, 841(1-2):160-169, 1999.
280. Turchi, J., and Sarter, M. Antisense oligodeoxynucleotide-induced suppression of basal forebrain NMDA-NR1 subunits selectively impairs visual attentional performance in rats. European Journal of Neuroscience, 14(1):103-117, 2001a.
281. Turchi, J., and Sarter, M. Bidirectional modulation of basal forebrain N-methyl-D-aspartate receptor function differentially affects visual attention but not visual discrimination performance. Neuroscience, 104(2):407-417, 2001b.
282. Usuda, I., Tanaka, K., and Chiba, T. Efferent projections of the nucleus accumbens in the rat with special reference to subdivision of the nucleus: Biotinylated dextran amine study. Brain Research, 797(1):73-93, 1998.
283. Velligan, D.I., Mahurin, R.K., Diamond, P.L., Hazleton, B.C., Eckert, S.L., and Miller, A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 25(1):21-31, 1997.
284. Venables, P.H. Input dysfunction in schizophrenia. In: Maher, B.A., ed. Progress in Experimental Personality Research. New York, NY: Academic Press, 1964. pp. 1-47.
285. Ventura, J., Nuechterlein, K.H., Lukoff, D., and Hardesty, J.P. A prospective study of stressful life events and schizophrenic relapse. Journal of Abnormal Psychology, 98(4):407-411, 1989.
286. Voytko, M.L. Cognitive functions of the basal forebrain cholinergic system in monkeys: Memory or attention? Behavioural Brain Research, 75(1-2):13-25, 1996.
287. Walaas, I., and Fonnum, F. Biochemical evidence for gamma-aminobutyrate containing fibres from the nucleus accumbens to the substantia nigra and ventral tegmental area in the rat. Neuroscience, 5(1):63-72, 1980.
288. Wassef, A.A., Dott, S.G., Harris, A., Brown, A., O'Boyle, M., Meyer, W.J., 3rd, and Rose, R.M. Critical review of GABA-ergic drugs in the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 19(3):222-232, 1999.
289. Webster, H.H., Rasmusson, D.D., Dykes, R.W., Schliebs, R., Schober, W., Bruckner, G., and Biesold, D. Long-term enhancement of evoked potentials in raccoon somatosensory cortex following co-activation of the nucleus basalis of Meynert complex and cutaneous receptors. Brain Research, 545(1-2):292-296, 1991.
290. Weinberger, D.R., and Lipska, B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground. Schizophrenia Research, 16(2):87-110, 1995.
291. Wells, B.G., Marken, P.A., Rickman, L.A., Brown, C.S., Hamann, G., and Grimmig, J. Characterizing anticholinergic abuse in community mental health. Journal of Clinical Psychopharmacology, 9(6):431-435, 1989.
292. Whitelaw, R.B., Markou, A., Robbins, T.W., and Everitt, B.J. Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology, 127(3):213-224, 1996.
293. Wolkowitz, O.M., and Pickar, D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. American Journal of Psychiatry, 148(6):714-726, 1991.
294. Wright, C.I., Beijer, A.V., and Groenewegen, H.J. Basal amygdaloid complex afferents to the rat nucleus accumbens are compartmentally organized. Journal of Neuroscience, 16(5):1877-1893, 1996.
295. Wu, M., Brudzynski, S.M., and Mogenson, G.J. Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion. Canadian Journal of Physiology and Pharmacology, 71(5-6):407-413, 1993.
296. Xiang, Z., Huguenard, J.R., and Prince, D.A. Cholinergic switching within neocortical inhibitory networks. Science, 281(5379):985-988, 1998.
297. Yamamoto, B.K., Pehek, E.A., and Meltzer, H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. Journal of Clinical Psychiatry, 55(Suppl B):8-14, 1994.
298. Yang, C.R., and Mogenson, G.J. Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens. Brain Research, 489(2):237-246, 1989.
299. You, Z.B., Tzschentke, T.M., Brodin, E., and Wise, R.A. Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: An in vivo microdialysis study in freely moving rats. Journal of Neuroscience, 18(16):6492-6500, 1998.
300. Young, A.M., Ahier, R.G., Upton, R.L., Joseph, M.H., and Gray, J.A. Increased extracellular dopamine in the nucleus accumbens of the rat during associative learning of neutral stimuli. Neuroscience, 83(4):1175-1183, 1998.
301. Young, W.S., 3rd, Alheid, G.F., and Heimer, L. The ventral pallidal projection to the mediodorsal thalamus: A study with fluorescent retrograde tracers and immunohistofluorescence. Journal of Neuroscience, 4(6):1626-1638, 1984.
302. Youngren, K.D., Daly, D.A., and Moghaddam, B. Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics, 264(1):289-293, 1993.
303. Yui, K., Goto, K., Ikemoto, S., Ishiguro, T., Angrist, B., Duncan, G.E., Sheitman, B.B., Lieberman, J.A., Bracha, S.H., and Ali, S.F. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization. Molecular Psychiatry, 4(6):512-523, 1999a.
304. Yui, K., Ishiguro, T., Goto, K., Ikemoto, S., and Kamata, Y. Spontaneous recurrence of methamphetamine psychosis: Increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. European Archives of Psychiatry and Clinical Neuroscience, 249(2):103-111, 1999b.
305. Zaborszky, L. Synaptic organization of basal forebrain cholinergic projection neurons. In: Levin, E., Decker, M.W., and Butcher, L.L., eds. Neurotransmitter Interactions and Cognitive Function. Boston, MA: Birkhauser, 1992. pp. 27-65.
306. Zaborszky, L., and Cullinan, W.E. Projections from the nucleus accumbens to cholinergic neurons of the ventral pallidum: A correlated light and electron microscopic double-immunolabeling study in rat. Brain Research, 570(1-2):92-101, 1992.
307. Zaborszky, L., and Cullinan, W.E. Direct catecholaminergic-cholinergic interactions in the basal forebrain: I. Dopamine-beta-hydroxylase- and tyrosine hydroxylase input to cholinergic neurons. Journal of Comparative Neurology, 374(4):535-554, 1996.
308. Zaborszky, L., Gaykema, R.P., Swanson, D.J., and Cullinan, W.E. Cortical input to the basal forebrain. Neuroscience, 79(4):1051-1078, 1997.
309. Zahm, D.S. Brog, J.S. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience, 50(4):751-767, 1992.
310. Zahm, D.S., and Heimer, L. Specificity in the efferent projections of the nucleus accumbens in the rat: Comparison of the rostral pole projection patterns with those of the core and shell. Journal of Comparative Neurology, 327(2):220-232, 1993.
311. Zahm, D.S., Jensen, S.L., Williams, E.S., and Martin, J.R., 3rd Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell. European Journal of Neuroscience, 11(4):1119-1126, 1999.
312. Zahrt, J., Taylor, J.R., Mathew, R.G., and Arnsten, A.F. Supra-normal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. Journal of Neuroscience, 17(21):8528-8535, 1997.